NeoGenomics Laboratories’ Post

Tamoxifen is a selective estrogen receptor modulator (SERM) commonly used to treat estrogen receptor-positive breast cancer in both pre- and post-menopausal women.

Always great to talk to Jeff about the vision and journey of CancerLinQ®, founded by American Society of Clinical Oncology (ASCO) and now an initiative of ConcertAI - Robert Miller https://lnkd.in/dDfy7nP3 #oncodaily #oncology #cancer #technology #data #AI #precisiononcology #RWD #CancerResearch #oncologydata

One of our co-founders, Dr Nina Fuller-Shavel, has recently published a review on integrative oncology approach to supporting immune checkpoint inhibitors with one of our expert panel members, Dr Jon Krell. We are preparing some materials to help people on ICI therapy learn key points of the article below with a helpful graphical overview, and we look forward to releasing this later in the month. https://lnkd.in/gqJt_Bx5 #immunotherapy #integrativeoncology #cancersupport #cancercare #lifestylemedicine

The Cutaneous Oncology Program at Washington University School of Medicine in St. Louis, co-led by Ryan Fields, MD, George Ansstas, MD, and Lynn Cornelius, MD, will soon be able to administer tumor-infiltrating lymphocyte (TIL) therapy for certain adult patients with metastatic melanoma, an aggressive skin cancer that has spread to other parts of the body, after the therapy recently received approval from the Food and Drug Administration. Learn more about the team's work at Siteman Cancer Center, how the therapy will help those with melanoma, and how this therapy may be applied in other settings in the future: https://lnkd.in/dPvR_Z5a

At #AACR24, look out for new data on the clinical utility of our Methylation Platform across the cancer continuum and the impact of multi-cancer early detection testing. The new data will highlight the potential of our targeted Methylation Platform across early detection and precision oncology settings. See the details here, including three oral presentations from GRAIL: https://lnkd.in/dPSD9Zf2

Evaluating the Impact of Metastatic Breast Cancer on Patients: An expert panel discusses the clinical and economic impact of metastatic breast cancer (mBC) on patients, the prognosis for those with mBC, the three FDA-approved CDK4/6 inhibitors for HR+/HER2- mBC, and the importance of overall survival as a clinical trial endpoint and its relevance to clinical practice. #finance #pharmacy #lifesciences

1 in 5 breast cancer patients will develop lymphedema, leading to complex and lifelong challenges. Early detection using Bioimpedance Spectroscopy (BIS) can make a significant difference. Discover how a prospective Lymphedema Surveillance Program can support your practice in improving patient outcomes. Learn more about the impact of early intervention and how BIS technology can help prevent chronic BCRL. 🔗https://ow.ly/9Gl050T00yc #BCRL #LymphedemaPrevention #EarlyDetection #BreastCancerCare

New Series Alert! Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, leads a panel discussion about CDK4/6 inhibitor use in high-risk early breast cancer with experts Naomi Dempsey, MD; Joyce O'Shaughnessy, MD; and Hope S. Rugo, MD, FASCO. Tune in to learn about trial updates, best practices in managing toxicity profiles, and financial challenges to navigate while optimizing patient outcomes. Watch here: https://bit.ly/4eGWTru #BreastCancer #ManagedCare

Exciting News from Carevive: Elevating Patient Experience in Oncology Research! Our Real-World Evidence (RWE) team, alongside our esteemed partners, recently showcased groundbreaking posters at prestigious conferences including ISPOR, ASCO, ASCO Quality, and ASH. These presentations, the culmination of collaborative efforts with leading academic institutions, underscore our commitment to advancing oncology research. We're proud to announce a significant milestone: the publication of three posters in collaboration with Takeda, shedding light on the patient experience in various hematologic malignancies. These publications mark our inaugural joint endeavors with industry, reinforcing our dedication to impactful partnerships. At Carevive, our mission to spearhead patient experience data in oncology remains unwavering. As we continue to build our 2024 collection, we invite you to explore our 2023 repository of publications and posters. https://lnkd.in/eceMxc3x Aaron Galaznik Keri Collette Mordecai Kramer Emelly Rusli Bruno Lempernesse Nadia Still DNP, RN April Boyd #carevive #digitaloncology #cancer #cancercare #oncology #patientreportedoutcomes #oncologydata  #clinicalinnovation #drugcommercialization #RWD #RWE #smartdata

Fortrea's expert panel will explore the current and future landscape of these CAR-T therapy, highlighting its diverse applications and potential. From revolutionizing treatment approaches in non-oncological diseases to leveraging operational oncology experience for broader therapeutic insights, this webinar will provide valuable lessons and insights into the transformative power CAR-T therapy across various therapeutics.